Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM206DNA + VM206Ad appears to be a combination product consisting of two investigational gene therapy agents: VM206DNA (a DNA-based component) and VM206Ad (an adenoviral vector). These agents are likely designed as part of a gene therapy approach, where the DNA plasmid encodes a therapeutic gene and the adenoviral vector acts either as a delivery vehicle or as a priming/boosting agent. The exact mechanism of action and targeted disease indications are not specified in publicly available authoritative sources as of September 2025. No mechanism, modality, regulatory status, or sponsoring company has been confirmed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VM206DNA + VM206Ad.